Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 674

1.

Safety and efficacy of novel malaria vaccine regimens of RTS,S/AS01B alone, or with concomitant ChAd63-MVA-vectored vaccines expressing ME-TRAP.

Rampling T, Ewer KJ, Bowyer G, Edwards NJ, Wright D, Sridhar S, Payne R, Powlson J, Bliss C, Venkatraman N, Poulton ID, de Graaf H, Gbesemete D, Grobbelaar A, Davies H, Roberts R, Angus B, Ivinson K, Weltzin R, Rajkumar BY, Wille-Reece U, Lee C, Ockenhouse C, Sinden RE, Gerry SC, Lawrie AM, Vekemans J, Morelle D, Lievens M, Ballou RW, Lewis DJM, Cooke GS, Faust SN, Gilbert S, Hill AVS.

NPJ Vaccines. 2018 Oct 9;3:49. doi: 10.1038/s41541-018-0084-2. eCollection 2018.

PMID:
30323956
2.

Development of a Molecular Adjuvant to Enhance Antigen-Specific CD8+ T Cell Responses.

Halbroth BR, Sebastian S, Poyntz HC, Bregu M, Cottingham MG, Hill AVS, Spencer AJ.

Sci Rep. 2018 Oct 9;8(1):15020. doi: 10.1038/s41598-018-33375-1.

3.

Prime and target immunization protects against liver-stage malaria in mice.

Gola A, Silman D, Walters AA, Sridhar S, Uderhardt S, Salman AM, Halbroth BR, Bellamy D, Bowyer G, Powlson J, Baker M, Venkatraman N, Poulton I, Berrie E, Roberts R, Lawrie AM, Angus B, Khan SM, Janse CJ, Ewer KJ, Germain RN, Spencer AJ, Hill AVS.

Sci Transl Med. 2018 Sep 26;10(460). pii: eaap9128. doi: 10.1126/scitranslmed.aap9128.

PMID:
30257955
4.

Iron Status and Associated Malaria Risk Among African Children.

Muriuki JM, Mentzer AJ, Kimita W, Ndungu FM, Macharia AW, Webb EL, Lule SA, Morovat A, Hill AVS, Bejon P, Elliott AM, Williams TN, Atkinson SH.

Clin Infect Dis. 2018 Sep 14. doi: 10.1093/cid/ciy791. [Epub ahead of print]

PMID:
30219845
5.

CXCR3+ T Follicular Helper Cells Induced by Co-Administration of RTS,S/AS01B and Viral-Vectored Vaccines Are Associated With Reduced Immunogenicity and Efficacy Against Malaria.

Bowyer G, Grobbelaar A, Rampling T, Venkatraman N, Morelle D, Ballou RW, Hill AVS, Ewer KJ.

Front Immunol. 2018 Jul 25;9:1660. doi: 10.3389/fimmu.2018.01660. eCollection 2018.

6.

Activation-induced Markers Detect Vaccine-Specific CD4⁺ T Cell Responses Not Measured by Assays Conventionally Used in Clinical Trials.

Bowyer G, Rampling T, Powlson J, Morter R, Wright D, Hill AVS, Ewer KJ.

Vaccines (Basel). 2018 Jul 31;6(3). pii: E50. doi: 10.3390/vaccines6030050.

7.

Qualified Biolayer Interferometry Avidity Measurements Distinguish the Heterogeneity of Antibody Interactions with Plasmodium falciparum Circumsporozoite Protein Antigens.

Dennison SM, Reichartz M, Seaton KE, Dutta S, Wille-Reece U, Hill AVS, Ewer KJ, Rountree W, Sarzotti-Kelsoe M, Ozaki DA, Alam SM, Tomaras GD.

J Immunol. 2018 Aug 15;201(4):1315-1326. doi: 10.4049/jimmunol.1800323. Epub 2018 Jul 13.

8.

Tailoring a Plasmodium vivax Vaccine To Enhance Efficacy through a Combination of a CSP Virus-Like Particle and TRAP Viral Vectors.

Atcheson E, Bauza K, Salman AM, Alves E, Blight J, Viveros-Sandoval ME, Janse CJ, Khan SM, Hill AVS, Reyes-Sandoval A.

Infect Immun. 2018 Aug 22;86(9). pii: e00114-18. doi: 10.1128/IAI.00114-18. Print 2018 Sep.

9.

Rational Zika vaccine design via the modulation of antigen membrane anchors in chimpanzee adenoviral vectors.

López-Camacho C, Abbink P, Larocca RA, Dejnirattisai W, Boyd M, Badamchi-Zadeh A, Wallace ZR, Doig J, Velazquez RS, Neto RDL, Coelho DF, Kim YC, Donald CL, Owsianka A, De Lorenzo G, Kohl A, Gilbert SC, Dorrell L, Mongkolsapaya J, Patel AH, Screaton GR, Barouch DH, Hill AVS, Reyes-Sandoval A.

Nat Commun. 2018 Jun 22;9(1):2441. doi: 10.1038/s41467-018-04859-5.

10.

The First Norovirus Longitudinal Seroepidemiological Study From Sub-Saharan Africa Reveals High Seroprevalence of Diverse Genotypes Associated With Host Susceptibility Factors.

Thorne L, Nalwoga A, Mentzer AJ, de Rougemont A, Hosmillo M, Webb E, Nampiija M, Muhwezi A, Carstensen T, Gurdasani D, Hill AV, Sandhu MS, Elliott A, Goodfellow I.

J Infect Dis. 2018 Jul 24;218(5):716-725. doi: 10.1093/infdis/jiy219.

11.

Immunopeptidomic Profiling of HLA-A2-Positive Triple Negative Breast Cancer Identifies Potential Immunotherapy Target Antigens.

Ternette N, Olde Nordkamp MJM, Müller J, Anderson AP, Nicastri A, Hill AVS, Kessler BM, Li D.

Proteomics. 2018 Jun;18(12):e1700465. doi: 10.1002/pmic.201700465.

12.

Corrigendum to "Heterologous Two-dose Vaccination with Simian Adenovirus and Poxvirus Vectors Elicits Long-lasting Cellular Immunity to Influenza Virus A in Healthy Adults" [EBioMedicine 29 (2018) 146-154].

Coughlan L, Sridhar S, Payne R, Edmans M, Milicic A, Venkatraman N, Lugonja B, Clifton L, Qi C, Folegatti PM, Lawrie AM, Roberts R, de Graaf H, Sukhtankar P, Faust SN, Lewis DJM, Lambe T, Hill AVS, Gilbert SC.

EBioMedicine. 2018 May;31:321. doi: 10.1016/j.ebiom.2018.05.001. Epub 2018 May 5. No abstract available.

13.

Genetic variation in VAC14 is associated with bacteremia secondary to diverse pathogens in African children.

Gilchrist JJ, Mentzer AJ, Rautanen A, Pirinen M, Mwarumba S, Njuguna P, Mturi N; Wellcome Trust Case-Control Consortium 2; Kenyan Bacteraemia Study Group, Williams TN, Scott JAG, Hill AVS.

Proc Natl Acad Sci U S A. 2018 Apr 17;115(16):E3601-E3603. doi: 10.1073/pnas.1802071115. Epub 2018 Mar 27. No abstract available.

14.

Risk of nontyphoidal Salmonella bacteraemia in African children is modified by STAT4.

Gilchrist JJ, Rautanen A, Fairfax BP, Mills TC, Naranbhai V, Trochet H, Pirinen M, Muthumbi E, Mwarumba S, Njuguna P, Mturi N, Msefula CL, Gondwe EN, MacLennan JM, Chapman SJ, Molyneux ME, Knight JC, Spencer CCA, Williams TN, MacLennan CA, Scott JAG, Hill AVS.

Nat Commun. 2018 Mar 9;9(1):1014. doi: 10.1038/s41467-017-02398-z.

15.

Population Turnover in Remote Oceania Shortly after Initial Settlement.

Lipson M, Skoglund P, Spriggs M, Valentin F, Bedford S, Shing R, Buckley H, Phillip I, Ward GK, Mallick S, Rohland N, Broomandkhoshbacht N, Cheronet O, Ferry M, Harper TK, Michel M, Oppenheimer J, Sirak K, Stewardson K, Auckland K, Hill AVS, Maitland K, Oppenheimer SJ, Parks T, Robson K, Williams TN, Kennett DJ, Mentzer AJ, Pinhasi R, Reich D.

Curr Biol. 2018 Apr 2;28(7):1157-1165.e7. doi: 10.1016/j.cub.2018.02.051. Epub 2018 Feb 28.

PMID:
29501328
16.

Adenovirus-prime and baculovirus-boost heterologous immunization achieves sterile protection against malaria sporozoite challenge in a murine model.

Yoshida K, Iyori M, Blagborough AM, Salman AM, Dulal P, Sala KA, Yamamoto DS, Khan SM, Janse CJ, Biswas S, Yoshii T, Yusuf Y, Tokoro M, Hill AVS, Yoshida S.

Sci Rep. 2018 Mar 1;8(1):3896. doi: 10.1038/s41598-018-21369-y.

17.

Language continuity despite population replacement in Remote Oceania.

Posth C, Nägele K, Colleran H, Valentin F, Bedford S, Kami KW, Shing R, Buckley H, Kinaston R, Walworth M, Clark GR, Reepmeyer C, Flexner J, Maric T, Moser J, Gresky J, Kiko L, Robson KJ, Auckland K, Oppenheimer SJ, Hill AVS, Mentzer AJ, Zech J, Petchey F, Roberts P, Jeong C, Gray RD, Krause J, Powell A.

Nat Ecol Evol. 2018 Apr;2(4):731-740. doi: 10.1038/s41559-018-0498-2. Epub 2018 Feb 27.

18.

Assessment of novel vaccination regimens using viral vectored liver stage malaria vaccines encoding ME-TRAP.

Bliss CM, Bowyer G, Anagnostou NA, Havelock T, Snudden CM, Davies H, de Cassan SC, Grobbelaar A, Lawrie AM, Venkatraman N, Poulton ID, Roberts R, Mange PB, Choudhary P, Faust SN, Colloca S, Gilbert SC, Nicosia A, Hill AVS, Ewer KJ.

Sci Rep. 2018 Feb 21;8(1):3390. doi: 10.1038/s41598-018-21630-4.

19.

Precision Medicine in Type 2 Diabetes: Clinical Markers of Insulin Resistance Are Associated With Altered Short- and Long-term Glycemic Response to DPP-4 Inhibitor Therapy.

Dennis JM, Shields BM, Hill AV, Knight BA, McDonald TJ, Rodgers LR, Weedon MN, Henley WE, Sattar N, Holman RR, Pearson ER, Hattersley AT, Jones AG; MASTERMIND Consortium.

Diabetes Care. 2018 Apr;41(4):705-712. doi: 10.2337/dc17-1827. Epub 2018 Jan 31.

PMID:
29386249
20.

Safety and Immunogenicity of Malaria Vectored Vaccines Given with Routine Expanded Program on Immunization Vaccines in Gambian Infants and Neonates: A Randomized Controlled Trial.

Mensah VA, Roetynck S, Kanteh EK, Bowyer G, Ndaw A, Oko F, Bliss CM, Jagne YJ, Cortese R, Nicosia A, Roberts R, D'Alessio F, Leroy O, Faye B, Kampmann B, Cisse B, Bojang K, Gerry S, Viebig NK, Lawrie AM, Clarke E, Imoukhuede EB, Ewer KJ, Hill AVS, Afolabi MO.

Front Immunol. 2017 Nov 20;8:1551. doi: 10.3389/fimmu.2017.01551. eCollection 2017.

21.

An in vitro assay to measure antibody-mediated inhibition of P. berghei sporozoite invasion against P. falciparum antigens.

Rodríguez-Galán A, Salman AM, Bowyer G, Collins KA, Longley RJ, Brod F, Ulaszewska M, Ewer KJ, Janse CJ, Khan SM, Hafalla JC, Hill AVS, Spencer AJ.

Sci Rep. 2017 Dec 5;7(1):17011. doi: 10.1038/s41598-017-17274-5.

22.

Human vaccination against RH5 induces neutralizing antimalarial antibodies that inhibit RH5 invasion complex interactions.

Payne RO, Silk SE, Elias SC, Miura K, Diouf A, Galaway F, de Graaf H, Brendish NJ, Poulton ID, Griffiths OJ, Edwards NJ, Jin J, Labbé GM, Alanine DG, Siani L, Di Marco S, Roberts R, Green N, Berrie E, Ishizuka AS, Nielsen CM, Bardelli M, Partey FD, Ofori MF, Barfod L, Wambua J, Murungi LM, Osier FH, Biswas S, McCarthy JS, Minassian AM, Ashfield R, Viebig NK, Nugent FL, Douglas AD, Vekemans J, Wright GJ, Faust SN, Hill AV, Long CA, Lawrie AM, Draper SJ.

JCI Insight. 2017 Nov 2;2(21). pii: 96381. doi: 10.1172/jci.insight.96381. [Epub ahead of print]

23.

Chimpanzee adenoviral vectors as vaccines for outbreak pathogens.

Ewer K, Sebastian S, Spencer AJ, Gilbert S, Hill AVS, Lambe T.

Hum Vaccin Immunother. 2017 Dec 2;13(12):3020-3032. doi: 10.1080/21645515.2017.1383575. Epub 2017 Oct 30. Review.

24.

Random non-fasting C-peptide testing can identify patients with insulin-treated type 2 diabetes at high risk of hypoglycaemia.

Hope SV, Knight BA, Shields BM, Hill AV, Choudhary P, Strain WD, McDonald TJ, Jones AG.

Diabetologia. 2018 Jan;61(1):66-74. doi: 10.1007/s00125-017-4449-2. Epub 2017 Oct 5.

25.

Vaccines against Ebola virus.

Venkatraman N, Silman D, Folegatti PM, Hill AVS.

Vaccine. 2018 Aug 28;36(36):5454-5459. doi: 10.1016/j.vaccine.2017.07.054. Epub 2017 Aug 2.

PMID:
28780120
26.

Adjuvanting a viral vectored vaccine against pre-erythrocytic malaria.

Milicic A, S Rollier C, Tang CK, Longley R, Hill AVS, Reyes-Sandoval A.

Sci Rep. 2017 Aug 4;7(1):7284. doi: 10.1038/s41598-017-07246-0.

27.

Human vaccination against Plasmodium vivax Duffy-binding protein induces strain-transcending antibodies.

Payne RO, Silk SE, Elias SC, Milne KH, Rawlinson TA, Llewellyn D, Shakri AR, Jin J, Labbé GM, Edwards NJ, Poulton ID, Roberts R, Farid R, Jørgensen T, Alanine DG, de Cassan SC, Higgins MK, Otto TD, McCarthy JS, de Jongh WA, Nicosia A, Moyle S, Hill AV, Berrie E, Chitnis CE, Lawrie AM, Draper SJ.

JCI Insight. 2017 Jun 15;2(12). pii: 93683. doi: 10.1172/jci.insight.93683. [Epub ahead of print]

28.

Development of an objective gene expression panel as an alternative to self-reported symptom scores in human influenza challenge trials.

Muller J, Parizotto E, Antrobus R, Francis J, Bunce C, Stranks A, Nichols M, McClain M, Hill AVS, Ramasamy A, Gilbert SC.

J Transl Med. 2017 Jun 8;15(1):134. doi: 10.1186/s12967-017-1235-3.

29.

ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice.

Alharbi NK, Padron-Regalado E, Thompson CP, Kupke A, Wells D, Sloan MA, Grehan K, Temperton N, Lambe T, Warimwe G, Becker S, Hill AVS, Gilbert SC.

Vaccine. 2017 Jun 27;35(30):3780-3788. doi: 10.1016/j.vaccine.2017.05.032. Epub 2017 Jun 1.

30.

5T4 oncofoetal glycoprotein: an old target for a novel prostate cancer immunotherapy.

Cappuccini F, Pollock E, Stribbling S, Hill AVS, Redchenko I.

Oncotarget. 2017 Jul 18;8(29):47474-47489. doi: 10.18632/oncotarget.17666.

31.

Association between a common immunoglobulin heavy chain allele and rheumatic heart disease risk in Oceania.

Parks T, Mirabel MM, Kado J, Auckland K, Nowak J, Rautanen A, Mentzer AJ, Marijon E, Jouven X, Perman ML, Cua T, Kauwe JK, Allen JB, Taylor H, Robson KJ, Deane CM, Steer AC, Hill AVS; Pacific Islands Rheumatic Heart Disease Genetics Network.

Nat Commun. 2017 May 11;8:14946. doi: 10.1038/ncomms14946.

32.

Enhancing protective immunity to malaria with a highly immunogenic virus-like particle vaccine.

Collins KA, Snaith R, Cottingham MG, Gilbert SC, Hill AVS.

Sci Rep. 2017 Apr 19;7:46621. doi: 10.1038/srep46621.

33.

Rational development of a protective P. vivax vaccine evaluated with transgenic rodent parasite challenge models.

Salman AM, Montoya-Díaz E, West H, Lall A, Atcheson E, Lopez-Camacho C, Ramesar J, Bauza K, Collins KA, Brod F, Reis F, Pappas L, González-Cerón L, Janse CJ, Hill AVS, Khan SM, Reyes-Sandoval A.

Sci Rep. 2017 Apr 18;7:46482. doi: 10.1038/srep46482.

34.

Human genetic and metabolite variation reveals that methylthioadenosine is a prognostic biomarker and an inflammatory regulator in sepsis.

Wang L, Ko ER, Gilchrist JJ, Pittman KJ, Rautanen A, Pirinen M, Thompson JW, Dubois LG, Langley RJ, Jaslow SL, Salinas RE, Rouse DC, Moseley MA, Mwarumba S, Njuguna P, Mturi N; Wellcome Trust Case Control Consortium 2; Kenyan Bacteraemia Study Group, Williams TN, Scott JA, Hill AV, Woods CW, Ginsburg GS, Tsalik EL, Ko DC.

Sci Adv. 2017 Mar 8;3(3):e1602096. doi: 10.1126/sciadv.1602096. eCollection 2017 Mar.

35.

Cryopreservation-related loss of antigen-specific IFNγ producing CD4+ T-cells can skew immunogenicity data in vaccine trials: Lessons from a malaria vaccine trial substudy.

Ford T, Wenden C, Mbekeani A, Dally L, Cox JH, Morin M, Winstone N, Hill AVS, Gilmour J, Ewer KJ.

Vaccine. 2017 Apr 4;35(15):1898-1906. doi: 10.1016/j.vaccine.2017.02.038. Epub 2017 Mar 9.

36.

Evaluation of Plasmodium vivax Cell-Traversal Protein for Ookinetes and Sporozoites as a Preerythrocytic P. vivax Vaccine.

Alves E, Salman AM, Leoratti F, Lopez-Camacho C, Viveros-Sandoval ME, Lall A, El-Turabi A, Bachmann MF, Hill AV, Janse CJ, Khan SM, Reyes-Sandoval A.

Clin Vaccine Immunol. 2017 Apr 5;24(4). pii: e00501-16. doi: 10.1128/CVI.00501-16. Print 2017 Apr.

37.

Viral Vector Malaria Vaccines Induce High-Level T Cell and Antibody Responses in West African Children and Infants.

Bliss CM, Drammeh A, Bowyer G, Sanou GS, Jagne YJ, Ouedraogo O, Edwards NJ, Tarama C, Ouedraogo N, Ouedraogo M, Njie-Jobe J, Diarra A, Afolabi MO, Tiono AB, Yaro JB, Adetifa UJ, Hodgson SH, Anagnostou NA, Roberts R, Duncan CJ, Cortese R, Viebig NK, Leroy O, Lawrie AM, Flanagan KL, Kampmann B, Imoukhuede EB, Sirima SB, Bojang K, Hill AV, Nébié I, Ewer KJ.

Mol Ther. 2017 Feb 1;25(2):547-559. doi: 10.1016/j.ymthe.2016.11.003.

38.

The Threshold of Protection from Liver-Stage Malaria Relies on a Fine Balance between the Number of Infected Hepatocytes and Effector CD8+ T Cells Present in the Liver.

Spencer AJ, Longley RJ, Gola A, Ulaszewska M, Lambe T, Hill AV.

J Immunol. 2017 Mar 1;198(5):2006-2016. doi: 10.4049/jimmunol.1601209. Epub 2017 Jan 13.

39.

Probability of Transmission of Malaria from Mosquito to Human Is Regulated by Mosquito Parasite Density in Naïve and Vaccinated Hosts.

Churcher TS, Sinden RE, Edwards NJ, Poulton ID, Rampling TW, Brock PM, Griffin JT, Upton LM, Zakutansky SE, Sala KA, Angrisano F, Hill AV, Blagborough AM.

PLoS Pathog. 2017 Jan 12;13(1):e1006108. doi: 10.1371/journal.ppat.1006108. eCollection 2017 Jan.

40.

Shared and Distinct Aspects of the Sepsis Transcriptomic Response to Fecal Peritonitis and Pneumonia.

Burnham KL, Davenport EE, Radhakrishnan J, Humburg P, Gordon AC, Hutton P, Svoren-Jabalera E, Garrard C, Hill AVS, Hinds CJ, Knight JC.

Am J Respir Crit Care Med. 2017 Aug 1;196(3):328-339. doi: 10.1164/rccm.201608-1685OC.

41.

Assessment of the Plasmodium falciparum Preerythrocytic Antigen UIS3 as a Potential Candidate for a Malaria Vaccine.

Longley RJ, Halbroth BR, Salman AM, Ewer KJ, Hodgson SH, Janse CJ, Khan SM, Hill AV, Spencer AJ.

Infect Immun. 2017 Feb 23;85(3). pii: e00641-16. doi: 10.1128/IAI.00641-16. Print 2017 Mar.

42.

Safety, Immunogenicity and Efficacy of Prime-Boost Vaccination with ChAd63 and MVA Encoding ME-TRAP against Plasmodium falciparum Infection in Adults in Senegal.

Mensah VA, Gueye A, Ndiaye M, Edwards NJ, Wright D, Anagnostou NA, Syll M, Ndaw A, Abiola A, Bliss C, Gomis JF, Petersen I, Ogwang C, Dieye T, Viebig NK, Lawrie AM, Roberts R, Nicosia A, Faye B, Gaye O, Leroy O, Imoukhuede EB, Ewer KJ, Bejon P, Hill AV, Cisse B; MVVC group.

PLoS One. 2016 Dec 15;11(12):e0167951. doi: 10.1371/journal.pone.0167951. eCollection 2016.

43.

Changes in Serological Immunology Measures in UK and Kenyan Adults Post-controlled Human Malaria Infection.

Hodgson SH, Llewellyn D, Silk SE, Milne KH, Elias SC, Miura K, Kamuyu G, Juma EA, Magiri C, Muia A, Jin J, Spencer AJ, Longley RJ, Mercier T, Decosterd L, Long CA, Osier FH, Hoffman SL, Ogutu B, Hill AV, Marsh K, Draper SJ.

Front Microbiol. 2016 Oct 13;7:1604. eCollection 2016.

44.

Genetic Factors of the Disease Course after Sepsis: A Genome-Wide Study for 28Day Mortality.

Scherag A, Schöneweck F, Kesselmeier M, Taudien S, Platzer M, Felder M, Sponholz C, Rautanen A, Hill AVS, Hinds CJ, Hossain H, Suttorp N, Kurzai O, Slevogt H, Giamarellos-Bourboulis EJ, Armaganidis A, Trips E, Scholz M, Brunkhorst FM.

EBioMedicine. 2016 Oct;12:239-246. doi: 10.1016/j.ebiom.2016.08.043. Epub 2016 Sep 15.

45.

Highly-Immunogenic Virally-Vectored T-cell Vaccines Cannot Overcome Subversion of the T-cell Response by HCV during Chronic Infection.

Swadling L, Halliday J, Kelly C, Brown A, Capone S, Ansari MA, Bonsall D, Richardson R, Hartnell F, Collier J, Ammendola V, Del Sorbo M, Von Delft A, Traboni C, Hill AV, Colloca S, Nicosia A, Cortese R, Klenerman P, Folgori A, Barnes E.

Vaccines (Basel). 2016 Aug 2;4(3). pii: E27. doi: 10.3390/vaccines4030027.

46.

Influence of adenovirus and MVA vaccines on the breadth and hierarchy of T cell responses.

Rollier CS, Hill AVS, Reyes-Sandoval A.

Vaccine. 2016 Aug 31;34(38):4470-4474. doi: 10.1016/j.vaccine.2016.07.050. Epub 2016 Jul 30.

47.

Safety and High Level Efficacy of the Combination Malaria Vaccine Regimen of RTS,S/AS01B With Chimpanzee Adenovirus 63 and Modified Vaccinia Ankara Vectored Vaccines Expressing ME-TRAP.

Rampling T, Ewer KJ, Bowyer G, Bliss CM, Edwards NJ, Wright D, Payne RO, Venkatraman N, de Barra E, Snudden CM, Poulton ID, de Graaf H, Sukhtankar P, Roberts R, Ivinson K, Weltzin R, Rajkumar BY, Wille-Reece U, Lee CK, Ockenhouse CF, Sinden RE, Gerry S, Lawrie AM, Vekemans J, Morelle D, Lievens M, Ballou RW, Cooke GS, Faust SN, Gilbert S, Hill AV.

J Infect Dis. 2016 Sep 1;214(5):772-81. doi: 10.1093/infdis/jiw244. Epub 2016 Jun 15.

48.

Viral vectors as vaccine platforms: from immunogenicity to impact.

Ewer KJ, Lambe T, Rollier CS, Spencer AJ, Hill AV, Dorrell L.

Curr Opin Immunol. 2016 Aug;41:47-54. doi: 10.1016/j.coi.2016.05.014. Epub 2016 Jun 7. Review.

PMID:
27286566
49.

Polymorphism in a lincRNA Associates with a Doubled Risk of Pneumococcal Bacteremia in Kenyan Children.

Kenyan Bacteraemia Study Group; Wellcome Trust Case Control Consortium 2 (WTCCC2), Rautanen A, Pirinen M, Mills TC, Rockett KA, Strange A, Ndungu AW, Naranbhai V, Gilchrist JJ, Bellenguez C, Freeman C, Band G, Bumpstead SJ, Edkins S, Giannoulatou E, Gray E, Dronov S, Hunt SE, Langford C, Pearson RD, Su Z, Vukcevic D, Macharia AW, Uyoga S, Ndila C, Mturi N, Njuguna P, Mohammed S, Berkley JA, Mwangi I, Mwarumba S, Kitsao BS, Lowe BS, Morpeth SC, Khandwalla I; Kilifi Bacteraemia Surveillance Group, Blackwell JM, Bramon E, Brown MA, Casas JP, Corvin A, Duncanson A, Jankowski J, Markus HS, Mathew CG, Palmer CNA, Plomin R, Sawcer SJ, Trembath RC, Viswanathan AC, Wood NW, Deloukas P, Peltonen L, Williams TN, Scott JAG, Chapman SJ, Donnelly P, Hill AVS, Spencer CCA.

Am J Hum Genet. 2016 Jun 2;98(6):1092-1100. doi: 10.1016/j.ajhg.2016.03.025. Epub 2016 May 26.

50.

Safety and Immunogenicity of ChAd63 and MVA ME-TRAP in West African Children and Infants.

Afolabi MO, Tiono AB, Adetifa UJ, Yaro JB, Drammeh A, Nébié I, Bliss C, Hodgson SH, Anagnostou NA, Sanou GS, Jagne YJ, Ouedraogo O, Tamara C, Ouedraogo N, Ouedraogo M, Njie-Jobe J, Diarra A, Duncan CJ, Cortese R, Nicosia A, Roberts R, Viebig NK, Leroy O, Lawrie AM, Flanagan KL, Kampman B, Bejon P, Imoukhuede EB, Ewer KJ, Hill AV, Bojang K, Sirima SB.

Mol Ther. 2016 Aug;24(8):1470-7. doi: 10.1038/mt.2016.83. Epub 2016 Apr 25.

Supplemental Content

Support Center